Cancer therapies crisis in the USA

Expert Review of Anticancer Therapy

Volumn 3, Issue 5, 2003, Pages 579-582

  Grillo López, Antonio J ^a  

^a Neoplastic and Autoimmune Diseases Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEFITINIB; IMATINIB; NEW DRUG; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURGERY; CANCER THERAPY; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; DRUG TARGETING; EDITORIAL; GENE THERAPY; HEALTH CARE SYSTEM; HUMAN; LIFESPAN; NONHODGKIN LYMPHOMA; PRACTICE GUIDELINE; PUBLICATION; UNITED STATES;

EID: 0242319623     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.5.579     Document Type: Editorial

References (4)

1. Grillo-López AJ. Curative therapies for NHL: a question of time! Monoclonal antibodies in the treatment of hematologic malignancies - a special issue. Curr. Pharm. Biotechnol. 2(4), 279-280 (2001).
2. Grillo-López AJ. Rituximab: clinical development of the first therapeutic antibody for cancer. In: Applications of Pharmaceutical Biotechnology, A Comprehensive Textbook. Kayser O, Müller R (Eds), Wiley-VCH Verlag, Weinheim, Germany (In Press).
3. ESMO Minimum clinical recommendations for diagnosis, treatment and follow-up of newly diagnosed follicular lymphoma. Ann. Oncol. 14, 1163-1164 (2003).
4. Grillo-López AJ. AntiCD20 mAbs: modifying therapeutic strategies and outcomes in the treatment of lymphoma patients. Expert Rev. Anticancer Ther. 2(3), 323-329 (2002).